Safety and Tolerability Study of Ragweed SLIT Tablets

Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets Given in Single Rising Doses and in Multi Dose Regimens to Subjects With an Allergy to Ragweed Pollen.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01224834

Enrollment

Registered

2010-10-20

Start date

2009-01-31

Completion date

2009-10-31

Last updated

2010-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ragweed Pollen Allergy, Rhinitis, Allergic, Seasonal

Keywords

Ragweed, allergy, sublingual immunotherapy

Brief summary

The purpose of this study is to determine the safety and tolerability of several doses of ragweed pollen allergen extract administered as sublingual tablets in subjects with allergic rhinitis to ragweed.

Interventions

DRUGSublingual tablet of ragweed pollen allergen extract

administered once a day over 10 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* written consent * male or female subjects from 18 yo 60 years old and in general good health * for women of child bearing potential: negative urine pregnancy test and use of medically effective contraceptive method * symptoms of ragweed pollen induced allergic rhinitis for at least the last 2 years * sensitization to ragweed pollen as demonstrated with positive skin prick test to ragweed pollen and specific IgE level (ragweed pollen) \> 0.70 kU/l at screening * FEV1 at least of 80% of predicted value at screening

Exclusion criteria

* past or current disease which, as judged by the investigator, may affect the outcome of this study * history of life-threatening asthma * asthma requiring daily treatment (whatever the pharmaceutical class) * pregnant or lactating women * subjects who previously received desensitisation treatment to ragweed pollen and/or other Asteraceae or who plan to start desensitisation treatment during this study * symptoms during the treatment phase due to a sensitivity to a second allergen * subjects treated with ongoing immunotherapy with another allergen

Design outcomes

Primary

Measure	Time frame
Safety, tolerability as indicated by adverse events and safety laboratory evaluation assessed every day over 2 weeks	2 weeks

Secondary

Measure	Time frame
Immunological markers (IgE and IgG4)	2 weeks

Countries

Hungary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026